Tirzepatide

Tirzepatide is a novel, once-weekly injectable medication belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. It works by stimulating the GLP-1 receptor, which leads to increased insulin secretion, decreased glucagon secretion, and reduced food intake. Tirzepatide is developed for the management of type 2 diabetes mellitus and obesity.

Indications

Tirzepatide is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, and for adults with obesity to aid in weight management.

Dosage

The recommended starting dosage of tirzepatide for both type 2 diabetes and obesity is 5 mg once weekly, administered subcutaneously. The dosage may be increased to 10 mg once weekly after 4 weeks based on individual patient response and tolerability.

Contra-Indications

Tirzepatide is contraindicated in patients with a history of hypersensitivity to tirzepatide or any of its components.

Special Precautions

Caution should be exercised when prescribing tirzepatide to patients with a history of pancreatitis, diabetic retinopathy, renal impairment, or thyroid tumors. It should be used with caution in patients with a history of gastroparesis.

Side Effects

Common side effects of tirzepatide may include nausea, vomiting, diarrhea, abdominal pain, constipation, and injection site reactions. Other potential adverse reactions include pancreatitis, hypoglycemia, acute kidney injury, and allergic reactions.

Drug Interactions

Tirzepatide may interact with other medications, including oral contraceptives, digoxin, and warfarin. Close monitoring and dosage adjustments may be necessary when co-administering tirzepatide with these drugs.